Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2018

View Archived Issues

Ribomic submits IND for anti-FGF-2 candidate

Phase III EASE-2 and EASE-3 trials of empagliflozin in type 1 diabetes meet primary endpoint

Aerpio and Gossamer Bio enter exclusive license agreement for AKB-4924

Biktarvy approved in Europe for the treatment of HIV-1 infection

Phase Ib trial results for enzalutamide/CC-115 for metastatic castration-resistant prostate cancer

Aurinia expands voclosporin clinical development program

EMA validates Giapreza MAA

Pivotal phase III study of Qzytir in acute urticaria meets key endpoints

Preliminary results of phase II study of entinostat/pembrolizumab in MSS colorectal cancer

FDA approves Epidiolex for seizures associated with LGS and Dravet syndrome

FDA grants priority review to baloxavir marboxil NDA for influenza

Clinuvel files NDA for Scenesse for erythropoietic protoporphyria

ContraVir doses first subject in first-in-human study of CRV-431

Sophiris reports interim data from phase IIb study of topsalysin for prostate cancer

Cerenis completes enrollment in TARGET study of CER-001 in esophageal cancer

Pulmatrix reports topline results from phase I/Ib study of Pulmazole

AbbVie and Calibr establish T-cell therapy collaboration for cancer

FDA grants priority review to sNDA for Imbruvica with rituximab in Waldenstrom's macroglobulinemia

University of KwaZulu-Natal patents isatin derivatives

Universitaet Hamburg divulges nucleoside triphosphate prodrug antivirals

Roche, Genentech describe RIP-1 inhibitors

Merck & Co. presents HIV integrase inhibitors

EPZ-011989 demonstrates promising antitumor activity in preclinical models of epithelioid sarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...